EMA follows FDA to approve Roche's Tecentriq combo for frontline use in triple negative breast cancer

Months after Roche secured US approval for its checkpoint inhibitor Tecentriq, in combination with Celgene’s Abraxane, for frontline use in an aggressive, tough-to-treat subgroup of breast cancer patients — the EU has followed suit.